THE DEFINITIVE GUIDE TO HEMGENIX

Variety of qualified sufferers: CDEC talked about the uncertainty in the amount of sufferers with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people who will be categorized as having delicate or average disease can have a significant bleeding ph